Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
21 hedge funds and large institutions have $7.02M invested in Evoke Pharma in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 4 closing their positions.
38% more capital invested
Capital invested by funds: $5.07M → $7.02M (+$1.95M)
0.01% more ownership
Funds ownership: 0.09% → 0.09% (+0.01%)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$190K |
| 2 |
Millennium Management
New York
|
+$147K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$134K |
| 4 |
VF
Virtu Financial
New York
|
+$106K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Precept Management
Dallas,
Texas
|
-$243K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$39K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$6K |
EVOK Hedge Fund Activity: Q3 2017 in Review
21 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2017, worth a combined $7.02M — up 38% from $5.07M a quarter earlier.
Fund positioning in EVOK was balanced in Q3 2017: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 0 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $190K. The largest seller was Precept Management, exiting entirely with an estimated $243K sold.
- 21 institutional investors held Evoke Pharma (EVOK) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $7.02M of Evoke Pharma stock for Q3 2017, up 38% quarter-over-quarter.
- 4 funds opened new Evoke Pharma positions in Q3 2017 and 4 closed out, a net change of 0 holders.
- The largest Evoke Pharma buyer in Q3 2017 was Sphera Funds Management, an estimated $190K added.
- The largest Evoke Pharma seller in Q3 2017 was Precept Management, an estimated $243K sold.
Based on aggregated 13F filings for Q3 2017.